Variant alleles of the Wnt antagonist FRZB are determinants of hip shape and modify the relationship between hip shape and osteoarthritis
Arthritis & Rheumatism, 05/04/2012
Baker–LePain JC et al. – The rs288326 and rs7775 FRZB single–nucleotide polymorphisms (SNPs) are associated with the shape of the proximal femur. The presence of the rs288326 SNP alters the relationship between proximal femur shape and incident radiographic hip osteoarthritis (OA). These findings suggest that FRZB may serve an important role in determining hip shape and may modify the relationship between hip shape and OA.
A nested case–control study of Caucasian women, age ≥65 years, from the Study of Osteoporotic Fractures cohort was performed.
Cases (n = 451) were defined as subjects with radiographic evidence of incident hip OA during followup, while controls (n = 601) were subjects in whom no radiographic hip OA was identified at baseline or followup.
Statistical shape modeling (SSM) of the digitized hip radiographs was performed to assess the shape of the proximal femur, using 10 independent modes of shape variation generated by principal components analysis.
In addition, center–edge angle and acetabular depth were assessed as geometric measurements of acetabular shape.
The association of the rs288326 and rs7775 FRZB variant alleles with hip shape was analyzed using linear regression.
The effect of these alleles on the relationship between hip shape and radiographic hip OA was analyzed using a logistic regression model with or without inclusion of interaction terms.
The rs288326 and rs7775 alleles were associated with the shape of the proximal femur (SSM mode 2).
There was a significant interaction between the rs288326 SNP and proximal femur shape (SSM mode 2) in predicting radiographic hip OA (P for interaction = 0.022).
Among subjects with the rs288326 variant allele, there was an increased likelihood of radiographic hip OA in association with increasing quartiles of proximal femur shape mode 2 (for the fourth quartile of mode 2, odds ratio 2.5, 95% confidence interval 1.15, 5.25; P for linear trend = 0.02).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.